BioNTech (BNTX) to Release Earnings on Monday

BioNTech (NASDAQ:BNTX) is anticipated to post its quarterly earnings results before the market opens on Monday, March 10th. Analysts expect BioNTech to post earnings of $0.38 per share and revenue of $1.24 billion for the quarter. Individual that are interested in registering for the company’s earnings conference call can do so using this link.

BioNTech Stock Performance

NASDAQ BNTX opened at $108.78 on Friday. The company’s 50 day moving average is $116.91 and its 200-day moving average is $112.76. BioNTech has a 12-month low of $76.53 and a 12-month high of $131.49. The company has a quick ratio of 7.21, a current ratio of 7.33 and a debt-to-equity ratio of 0.01. The firm has a market cap of $26.08 billion, a P/E ratio of -51.80 and a beta of 0.30.

Wall Street Analyst Weigh In

A number of analysts recently weighed in on BNTX shares. Evercore ISI raised shares of BioNTech from an “in-line” rating to an “outperform” rating and upped their target price for the stock from $110.00 to $125.00 in a report on Tuesday, November 19th. Wells Fargo & Company started coverage on shares of BioNTech in a report on Wednesday, December 11th. They set an “overweight” rating and a $170.00 target price on the stock. HC Wainwright reaffirmed a “buy” rating and set a $150.00 target price on shares of BioNTech in a report on Monday, November 18th. Truist Financial started coverage on shares of BioNTech in a research note on Friday, January 10th. They issued a “buy” rating and a $172.00 price target for the company. Finally, BMO Capital Markets reissued an “outperform” rating on shares of BioNTech in a research note on Monday, December 2nd. Three research analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, BioNTech presently has a consensus rating of “Moderate Buy” and a consensus price target of $142.72.

BioNTech Company Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.